Mutations in CALR are responsible for 20%–30% of MPN cases and, like the other driver mutations, lead to the constitutive activation of Janus kinase–signal transducer and activator of transcription (JAK–STAT) signalling.9 Here, CALR is linked to myeloproliferative neoplasm.